Clinical Trial Update: Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects [Phase 1]

View source ↗

Summary

A Phase 1 multiple ascending dose trial of MSB0010841, an anti-IL17A/F nanobody, in psoriasis subjects has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• MSB0010841

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Psoriasis | Phase 1 | Status: COMPLETED | Results posted: 2017-01-19